TLTFF Archives - Page 2 of 3

Developments

Theralase to present Phase 2 NMIBC interim data at ASCO GU cancer symposium

Interim data from Theralase Technologies’ (TSXV:TLT; OTCQB:TLTFF) Phase 2 non-muscle invasive bladder cancer (NMIBC) clinical study has been accepted by the American Society of Clinical Oncology (ASCO) Genito Urinary...

January 25, 2023

Feature

Theralase advances pivotal clinical study of photo dynamic therapy to treat bladder cancer

Theralase Technologies (TSXV:TLT; OTCQB:TLTFF) expects to complete enrollment and primary study treatment in early 2024 of a Phase 2 pivotal clinical study for non-muscle invasive bladder cancer (NMIBC) with its light...

January 3, 2023

Markets

Research Capital: Theralase bladder cancer data trending ahead of Keytruda

Theralase Technologies (TSXV:TLT; OTCQB:TLTFF) released updated interim data from its Phase 2 pivotal trial with its key value driver, TLD-1433, activated by its proprietary TLC-3200 medical laser system, that Research...

November 30, 2022

Feature

Theralase Phase 2 NMIBC clinical study could support marketing application

Theralase Technologies (TSXV:TLT; OTCQB:TLTFF) has designed its Phase 2 clinical study in patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) based on FDA industry guidance issued in February 2018.

August 6, 2019

Developments

Theralase enrols first patient in Phase 2 NMIBC clinical study

Theralase Technologies (TSXV:TLT; OTCQB:TLTFF) enrolled the first patient in a Phase 2 clinical study of its light activated photodynamic compounds (PDC) in patients with non-muscle invasive bladder cancer (NMIBC) who...

July 29, 2019

Developments

Theralase in pact for U.S. clinical sites for Phase 2 NMIBC trial

Theralase Technologies (TSXV:TLT; OTCQB:TLTFF) signed an agreement with a trial management organization (TMO) to provide four-to-six U.S.-based urology study sites that will be able to commence enrolling and treating...

July 24, 2019

Developments

Theralase receives notice of acceptance for Multiwavelength PDT from Russian Patent Office

The Russian Patent Office issued a notice of acceptance for Theralase Technologies’ (TSXV:TLT) (OTCQB:TLTFF) Multiwavelength photodynamic therapy (PDT) patent application. The patent application will issue into a patent...

July 16, 2019

Developments

Theralase receives patent notice of acceptance for PD compounds in China

The Chinese patent office granted Theralase Technologies (TSXV:TLT; OTCQB:TLTFF) a notice of acceptance for its light activated photodynamic compounds (PDC) intended to safely and effectively destroy various cancers...

May 21, 2019

Developments

Theralase receives notice of acceptance from Chinese Patent Office

The Chinese Patent Office issued a notice of acceptance to Theralase Technologies (TSXV:TLT; OTCQB:TLTFF) for a patent application about its multi-wavelength photodynamic therapy (PDT). The patent validates the...

May 7, 2019

Developments

Theralase presents Phase 1b NMIBC study at AUA conference

Theralase Technologies’ (TSXV:TLT; OTCQB:TLTFF) presented its Phase 1b clinical study of its anti-cancer therapy (ACT) for non-muscle invasive bladder cancer (NMIBC) at the American Urological Association conference in...

May 6, 2019

Tag - TLTFF

Theralase to present Phase 2 NMIBC interim data at ASCO GU cancer symposium

Theralase advances pivotal clinical study of photo dynamic therapy to treat bladder cancer

Research Capital: Theralase bladder cancer data trending ahead of Keytruda

Theralase Phase 2 NMIBC clinical study could support marketing application

Theralase enrols first patient in Phase 2 NMIBC clinical study

Theralase in pact for U.S. clinical sites for Phase 2 NMIBC trial

Theralase receives notice of acceptance for Multiwavelength PDT from Russian Patent Office

Theralase receives patent notice of acceptance for PD compounds in China

Theralase receives notice of acceptance from Chinese Patent Office

Theralase presents Phase 1b NMIBC study at AUA conference

General

More